Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KH903 plus paclitaxel in second-line unresectable recurrent or metastatic gastric or GEJ adenocarcinoma
CTR20201384Phase 2Completed
- Sponsor
- Chengdu Kanghong Biotechnology Co., Ltd.
- Start
- Jul 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of conbercept in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Chengdu Kanghong Biotechnology Co., Ltd.. Started Jul 2020; status: completed.
02
Drugs
conbercept
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20201384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201384.